Niagen Bioscience, Inc. (NAGE) Q2 2026 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Niagen Bioscience, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.051 -- 00:00:05.255 Hello everyone. Thank you for joining us and welcome to the Niagen Bioscience second 00:00:05.255 -- 00:00:10.539 quarter 2026 earnings conference call. After today's prepared remarks, 00:00:10.539 -- 00:00:12.980 we will host a question and answer session. 00:00:12.980 -- 00:00:18.204 If you would like to ask a question, please press star 1 to raise your hand. 00:00:18.204 -- 00:00:22.207 To withdraw your question, press star 1 again. 00:00:22.207 -- 00:00:26.770 I will now hand the conference over to Lauren Borzanski, Assistant Controller. 00:00:26.770 -- 00:00:29.251 Please go ahead. 00:00:29.596 -- 00:00:34.899 Good afternoon and welcome to Niagen Bioscience, Inc.'s second quarter 2026 conference 00:00:34.899 -- 00:00:39.902 call. Joining me today are our Chief Executive Officer Rob Fried, 00:00:39.902 -- 00:00:45.286 Chief Financial Officer Ozan Pamir, and Senior Vice President of Scientific and Regulatory 00:00:45.286 -- 00:00:51.488 Affairs, Dr. Andrew Shao. Dr. Shao will join the call for Q&A. 00:00:51.710 -- 00:00:56.173 Before we begin, I'd like to remind everyone that today's call may include forward-looking 00:00:56.173 -- 00:01:01.592 statements. These statements relate to, among other things, our research and development 00:01:01.592 -- 00:01:06.794 activities, clinical trial plans and timing, regulatory filings, expansion 00:01:06.794 -- 00:01:11.055 into new markets, business development opportunities, and our expected financial and 00:01:11.055 -- 00:01:13.455 operating performance. 00:01:13.656 -- 00:01:17.978 These statements are based on our current expectations as of today and are subject to 00:01:17.978 -- 00:01:22.880 risks and uncertainties that could cause actual results to differ materially. 00:01:22.880 -...